Gu Han Pharmaceutical Co., Ltd.

Statement and Commitment of Independent Director Candidate - Luo Huaqing

Independent Director Nominee Statement and Commitment - Guo Dongfang

Independent Director Nominee Statement and Commitment - Lei Zhenhua

Independent Director Nominee Statement and Commitment - Luo Huaqing

Statement and Commitment of Independent Director Candidate - Lei Zhenhua

Statement and Commitment of Independent Director Candidate - Guo Dongfang

Announcement on the Election of the Company's Board of Directors

2025 Annual Shareholders Meeting Materials

Notice of 2025 Annual Shareholders' Meeting of GuoHan Pharmaceutical Group Co., Ltd.

Announcement of Resolutions from the 10th Board of Directors Temporary Meeting

Notice on the Progress of the Controlling Shareholder's Concerted Action Person Increasing Company Shares and the Equity Change Reaching a Multiple of 5%

CITIC Securities Co., Ltd. Financial Advisor's Verification Opinion on the Detailed Report of Equity Changes of Guohan Pharmaceutical Group Co., Ltd.

Detailed Report on Equity Changes of Guohan Pharmaceutical Group Co., Ltd.

Announcement on the Reappointment of the Accounting Firm

Announcement on the Remuneration and Performance Assessment Plan for Directors and Senior Management for 2026

Announcement of the 9th Meeting Resolution of the 10th Board of Directors

Q1 2026 Report

Independent Director's 2025 Performance Report (Huang Wenbiao)

Independent Director's 2025 Performance Report (Lei Zhenhua)

Independent Director's 2025 Performance Report (Luo Huaiqing)

Independent Director's 2025 Performance Report (Huang Zhengming)

Internal Control Audit Report

2025 Internal Control Self-Assessment Report

Announcement on the Company's Provision for Asset and Credit Impairment in 2025

Announcement on Proposed Signing of Related Party Transaction Agreements for Daily Operations

Announcement on Providing Guarantees for Wholly-Owned Subsidiaries to Apply for Bank Credit Lines

Announcement on the Estimated External Guarantee Limit for 2026

Asset Valuation Report of Guangdong Xiantong Pharmaceutical Co., Ltd.'s Goodwill-Containing Asset Group Involved in Goodwill Impairment Testing

Board of Directors' Audit Committee's Performance in 2025

Announcement on the Company's Uncovered Losses Reaching One-Third of the Total Paid-in Capital

Announcement on the Company Applying for Comprehensive Credit Lines from Banks

Announcement on Purchasing Directors' and Senior Management's Liability Insurance

Announcement on the Fulfillment of Performance Commitments for Equity Acquisition

Resolution Announcement of the 8th Meeting of the Tenth Board of Directors

Announcement on the 2025 Profit Distribution Plan

Guhan Pharmaceutical Group Co., Ltd.'s Special Audit Opinion on Guhan (Guangdong) Pharmaceutical Co., Ltd.'s 2025 Performance Commitment Fulfillment

Special Explanation on the Fulfillment of Performance Commitments in 2025

Special Verification Opinion on the Deduction of Operating Revenue in 2025

Assessment Report on the Accounting Firm's Performance in 2025

Report of the Board's Audit Committee on the Accounting Firm's Performance of Supervision Duties in 2025